

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

17 Jun 2026

### Study of the Serum levels of miRNA-16, miRNA-21, miRNA-217 and effects of L-carnitine on their levels , TNF- $\alpha$ , TGF- $\beta$ cytokines, Malondialdehyde and CRP in Nonalcoholic Steatohepatitis (NASH) patients under weight loss regimen

#### Protocol summary

##### Summary

The aim of this study is to investigate the Serum levels of microRNA-16, microRNA-21, microRNA-217 and effects of L-carnitine on their levels, Tumor Necrosis Factor- $\alpha$ , Tumor Growth Factor- $\beta$  cytokines, Malondialdehyde and C-Reactive Protein in Nonalcoholic Steatohepatitis patients under weight loss regimen. Inclusion criteria: age between 18-65 years; BMI $\geq$ 25 kg/m<sup>2</sup>, under weight loss regimen; ALT $\geq$ 1.5 fold norma;l Sonography showing Nonalcoholic Steatohepatitis, Exclusion criteria: not willing to collaborate;viral hepatitis; taking Insulin ;blood lipid-lowering agents; Antiinflammatory drugs(stroid and non stroid)and antioxidant supplement; smoking cigarettes. In this parallel randomized controlled trial, 92 men and women with NASH. will be recruited from nutrition clinic of Imam Reza hospital of Mashhad University of Medical Science. Blood samples will be obtained after an overnight fast before and after the study. Plasma miRNA will be extracted with Mirvana kit and then Real time PCR will be done. Other variables also will be measured. 3-days 24-recalls will be obtained at first and at the end of the study. Intervention group receives 2000 mg of L-carnitine as 2 vials and other group receives 2 placebo vials,before the meals, for 12 weeks. agents ,Antiinflammatory drugs(stroid and non stroid)and antioxidant supplement ,smoking cigarettes. Blood samples will be obtained after an overnight fast before and after the study.Plasma miRNA will be extracted with Mirvana kit and then Real time PCR will be done. TNF- $\alpha$  , TGF- $\beta$  cytokines, Malondialdehyde and CRP also will be measured. 3-days 24-recalls will be obtained at first and at the end of the study. Intervention group receives 2000 mg of L-carnitine as 2 vials and other group receives 2 placebo vials,before the meals, for 12 weeks.

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT201212052602N8**

Registration date: **2013-02-04, 1391/11/16**

Registration timing: **registered\_while\_recruiting**

Last update:

Update count: **0**

##### Registration date

2013-02-04, 1391/11/16

##### Registrant information

##### Name

Shahryar Egtesadi

##### Name of organization / entity

Iran University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 8877 9118

##### Email address

egtesadi@iums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

Vice Chancellor for Research Affairs of Tehran University of Medical Sciences

##### Expected recruitment start date

2013-01-20, 1391/11/01

##### Expected recruitment end date

2013-02-19, 1391/12/01

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty  
**Trial completion date**  
empty

**Scientific title**

Study of the Serum levels of miRNA-16, miRNA-21, miRNA-217 and effects of L-carnitine on their levels , TNF- $\alpha$  , TGF- $\beta$  cytokines, Malondialdehyde and CRP in Nonalcoholic Steatohepatitis (NASH) patients under weight loss regimen

**Public title**

Effects of L-carnitine on genetic, inflammation and antioxidant factors in Nonalcoholic Steatohepatitis patients.

**Purpose**

Treatment

**Inclusion/Exclusion criteria**

Inclusion criteria : age between 18-65 years; BMI $\geq$ 25 kg/m<sup>2</sup>, under weight loss regimen ; ALT $\geq$ 1.5 fold normal; Sonography showing Nonalcoholic Steatohepatitis ; Exclusion criteria: not willing toCollaborate; viral hepatitis; taking Insulin; blood lipid-lowering agents;Antiinflammatory drugs(stroid and non stroid) and antioxidant supplements; smoking cigarettes.

**Age**

From **18 years** old to **65 years** old

**Gender**

Both

**Phase**

N/A

**Groups that have been masked**

*No information*

**Sample size**

Target sample size: **92**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

**Placebo**

Used

**Assignment**

Parallel

**Other design features**

**Secondary Ids**

empty

**Ethics committees**

**1**

**Ethics committee**

**Name of ethics committee**

School of public Health,Tehran University of Medical Sciences

**Street address**

School of public Health, Alvand street,Argentina Square

**City**

Tehran

**Postal code**

**Approval date**

2012-11-17, 1391/08/27

**Ethics committee reference number**

91-03-161-19463-69987

**Health conditions studied**

**1**

**Description of health condition studied**

Nonalcoholic steatohepatitis

**ICD-10 code**

K75.9

**ICD-10 code description**

Nonalcoholic steatohepatitis( NASH)

**Primary outcomes**

**1**

**Description**

TNF- $\alpha$

**Timepoint**

At first of the study and 12th week

**Method of measurement**

labratory kit

**2**

**Description**

TGF- $\beta$

**Timepoint**

At first of the study and 12th week

**Method of measurement**

Sandwich Elisa

**3**

**Description**

Malondialdehyde

**Timepoint**

At first of the study and 12th week

**Method of measurement**

Sandwich Elisa

**4**

**Description**

CRP

**Timepoint**

At first of the study and 12th week

**Method of measurement**

labratory kit

**5**

**Description**

miRNA-16

**Timepoint**

At first of the study and 12th week

**Method of measurement**

RT-PCR

**6**

**Description**

miRNA-21

**Timepoint**

At first of the study and 12th week

**Method of measurement**

RT-PCR

**7**

**Description**

miRNA-217

**Timepoint**

At first of the study and 12th week

**Method of measurement**

RT-PCR

**Secondary outcomes**

empty

**Intervention groups**

**1**

**Description**

. Intervention group receives 2000 mg of L-carnitine as 2 vials,before the meals, for 12 weeks.

**Category**

Treatment - Drugs

**2**

**Description**

Control group receives 2000 mg of Placebo as 2 vials,before the meals, for 12 weeks.

**Category**

Treatment - Drugs

**Recruitment centers**

**1**

**Recruitment center**

**Name of recruitment center**

Nutrition clinic of Imam Reza hospital

**Full name of responsible person**

Dr. Mohsen Nematy

**Street address**

School Of Medicine, Ferdosi University of Medical Sciences, Azadi Square

**City**

Mashhad

**Sponsors / Funding sources**

**1**

**Sponsor**

**Name of organization / entity**

Vice Chancellor for Research of Tehran University of Medical Sciences

**Full name of responsible person**

Dr.Akbar Fotouhi

**Street address**

Vice Chancellor for Research of Tehran University of Medical Sciences, Ghods Ave, Keshavarz Blv

**City**

Tehran

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Vice Chancellor for Research of Tehran University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

empty

**Domestic or foreign origin**

empty

**Category of foreign source of funding**

empty

**Country of origin**

**Type of organization providing the funding**

empty

**Person responsible for general inquiries**

**Contact**

**Name of organization / entity**

School of public Health,Tehran University of Medical Sciences

**Full name of responsible person**

Dr.Shirin Amiri Moghaddam

**Position**

MD/Ph.D Student

**Other areas of specialty/work**

**Street address**

School of public Health, Alvand street, No 60,Argentina Square

**City**

Tehran

**Postal code**

**Phone**

+98 21 8877 9118

**Fax**

**Email**

amiri\_shirin14@yahoo.com

**Web page address**

**Person responsible for scientific inquiries**

**Contact**

**Name of organization / entity**

School of public Health, Tehran University of Medical Sciences

**Full name of responsible person**

Dr. Shahryar Eghtesadi

**Position**

Professor/Ph.D

**Other areas of specialty/work**

**Street address**

School of Public Health, No 60, Alvand Street, Argentina Square

**City**

Tehrane

**Postal code**

1516846514

**Phone**

+98 21 8877 9118 ext. 273

**Fax**

+98 21 8877 9487

**Email**

sh-eghtesadi@tums.ac.ir, egtesadi@yahoo.com

**Web page address**

**Person responsible for updating data**

**Contact**

**Name of organization / entity**

School of Public Health, Tehran University of Medical Sciences

**Full name of responsible person**

Dr. Shahryar Eghtesadi.

**Position**

Professor/Ph.D

**Other areas of specialty/work**

**Street address**

School of Public Health, Alvand Street No 60, Argentina Square

**City**

Tehran

**Postal code**

1516846514

**Phone**

+98 21 8877 9118 ext. 273

**Fax**

+98 21 8877 9487

**Email**

sh-eghtesadi@tums.ac.ir, egtesadi@yahoo.com

**Web page address**

**Sharing plan**

**Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*